Research Protocol

WOLVERINE - Research Protocal

Dosage Calculator → How to Reconstitute →

BPC-157 + TB-500

Quickstart Highlights

T

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide fragment derived from human gastric juice, studied for its cytoprotective and tissue-repair properties across gastrointestinal, musculoskeletal, and neurological systems[1][2]. TB-500 (Thymosin β4) is a 43-amino-acid peptide involved in cell migration, angiogenesis, and wound healing[3][4]. This blend combines both peptides for synergistic tissue-repair research applications.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL total concentration (~3.33 mg/mL of each peptide).
  • Typical daily range: 250–500 mcg BPC-157 + 250–500 mcg TB-500 (500–1,000 mcg total blend) once daily.
  • Easy measuring: At 6.67 mg/mL total, 1 unit = 0.01 mL ≈ 66.7 mcg total (~33.3 mcg of each peptide) on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days.

Standard / Gradual Approach (3 mL = ~6.67 mg/mL total)

Route: Subcutaneous injection | Frequency: Once daily

Week Daily Dose (total blend) Per-Peptide Dose Units (mL)
Weeks 1–2 500 mcg (0.5 mg) ~250 mcg each 7.5 units (0.075 mL)
Weeks 3–4 666 mcg (0.67 mg) ~333 mcg each 10 units (0.10 mL)
Weeks 5–8 1,000 mcg (1.0 mg) ~500 mcg each 15 units (0.15 mL)

For ≤10-unit (≤0.10 mL) administrations during Weeks 1–4, consider using 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
  3. Gently swirl or roll until fully dissolved (do not shake).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Advanced / Loading Phase (Optional)

Some protocols use a higher TB-500 loading dose during the first 2–4 weeks based on clinical monograph recommendations[5]. This schedule uses higher total blend volumes.

Route: Subcutaneous injection | Frequency: Once daily or split twice weekly for TB-500 loading

Phase Daily Dose (total blend) Per-Peptide Dose Units (mL)
Loading (Weeks 1–4) 1,500 mcg (1.5 mg) ~750 mcg each 22.5 units (0.225 mL)
Maintenance (Weeks 5–8) 1,000 mcg (1.0 mg) ~500 mcg each 15 units (0.15 mL)

Note: Advanced protocols consume peptide supplies faster. Plan vial quantities accordingly.

Plan based on a 4–8 week daily protocol (standard approach at ~1 mg/day maintenance).

  • Peptide Vials (BPC-157 + TB-500 20 mg Blend):

     

    • 4 weeks (28 doses at ~0.67–1.0 mg/day): 2 vials
    • 6 weeks (42 doses): 3 vials
    • 8 weeks (56 doses): 3–4 vials
  • Insulin Syringes (U-100):

     

    • Per week: 7 syringes (1/day)
    • 4 weeks: 28 syringes
    • 6 weeks: 42 syringes
    • 8 weeks: 56 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

     

    • 4 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 6 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

     

    • Per week: 14 swabs (2/day)
    • 4 weeks: 56 swabs → recommend 1 × 100-count box
    • 6 weeks: 84 swabs → recommend 1 × 100-count box
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes

Protocol Overview

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support tissue repair, wound healing, and musculoskeletal recovery in research contexts[1][3].
  • Schedule: Daily subcutaneous injections for 4–8 weeks; some protocols include 3-month-on / 6-week-off cycling.
  • Dose Range: 500–1,500 mcg total blend daily (providing ~250–750 mcg of each peptide).
  • Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL total) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; use within 14 days[6].

Dosing Protocol

Suggested daily titration approach.

  • Start: 500–666 mcg total blend daily (~250–333 mcg each peptide).
  • Target: 1,000 mcg total blend daily (~500 mcg each) by Weeks 3–8.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 4–8 weeks; optional cycling with 6-week breaks between courses.
  • Timing: Any consistent time; some prefer morning administration; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality and stability.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[6].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days and avoid freeze-thaw cycles[7].
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose properly in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and maintain absorption[8].
  • Inject near the site of injury when targeting localized tissue repair (within anatomical reason).
  • Document daily dose and site rotation to maintain consistency.
  • Both BPC-157 and TB-500 are prohibited in competitive sports by WADA[9].

How It Works

BPC-157 is a synthetic pentadecapeptide (15 amino acids) originally isolated from human gastric juice. Preclinical research indicates it exerts cytoprotective effects across multiple organ systems, promotes angiogenesis, modulates nitric oxide pathways, and interacts with growth-factor systems involved in tissue repair[1][2]. TB-500 (Thymosin β4) is a naturally occurring peptide that regulates actin polymerization, promotes cell migration, reduces inflammation, and supports wound healing and tissue regeneration[3][4]. The combination is hypothesized to provide complementary mechanisms for accelerated musculoskeletal and soft-tissue recovery.

Potential Benefits & Side Effects

Observations from preclinical and early clinical literature.

  • Tissue Repair: Both peptides demonstrate wound-healing, tendon-repair, and anti-inflammatory properties in animal models[1][3][10].
  • Gastrointestinal Support: BPC-157 shows gastroprotective and ulcer-healing effects in preclinical studies[2].
  • Safety Profile: Preclinical data indicate a wide safety margin for BPC-157 (no lethal dose up to ~20 mg/kg); TB-500 human tolerability studies report mild adverse events at doses up to 1,260 mg[5][11].
  • Possible Side Effects: Occasional mild injection-site reactions (redness, itching); rare reports of transient dizziness or nausea; long-term human safety data remain limited.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Prioritize adequate protein intake to support tissue synthesis and repair.
  • Combine with appropriate rehabilitation protocols when addressing musculoskeletal injuries.
  • Ensure quality sleep and stress management to optimize recovery and healing responses.
  • Stay hydrated and maintain balanced micronutrient intake (vitamins C, D, zinc) to support connective-tissue health.

.

References

For laboratory and research use only. Minimum 98% purity. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. This protocol is provided for educational and research purposes only and is not medical advice. The purchaser accepts full responsibility for safe handling, storage and lawful use.